Factors Affecting the Price of Pulmozyme

Pulmozyme (dornase alfa), a drug for cystic fibrosis, has a price shaped by key factors. 

Factors Affecting the Price of Pulmozyme

High R&D costs, from developing this recombinant enzyme to clinical trials proving its efficacy in reducing mucus viscosity, drive pricing. Genentech’s patent protection ensures market exclusivity, allowing premium rates. Production complexity, involving biologic manufacturing and strict quality control for its inhalable form, adds costs. Limited alternatives and high demand from cystic fibrosis patients further sustain prices. Regional healthcare policies, like insurance coverage and subsidies, also influence patient out-of-pocket expenses.